• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The final puff: Can New Zealand quit smoking for good?
Smoking kills. Ayesha Verrall has seen it up close. As a young resident physician in New Zealand’s public hospitals in the 2000s, Verrall watched smokers come into the emergency ward every night, struggling to breathe with their damaged lungs. Later, as an infectious disease specialist, she saw how smoking exacerbated illness in individuals diagnosed with tuberculosis and HIV/AIDS. She would tell them: “The best thing you can do to promote your health, other than take the pills, is to quit smoking.” Verrall is still urging citizens to give up cigarettes—no longer just one by one, but by the thousands. As New...
Source: ScienceNOW - December 9, 2022 Category: Science Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Environmental Pollution: An Under-recognized Threat to Children’s Health, Especially in Low- and Middle-Income Countries
Conclusions Patterns of disease are changing rapidly in LMICs. Pollution-related chronic diseases are becoming more common. This shift presents a particular problem for children, who are proportionately more heavily exposed than are adults to environmental pollutants and for whom these exposures are especially dangerous. Better quantification of environmental exposures and stepped-up efforts to understand how to prevent exposures that cause disease are needed in LMICs and around the globe. To confront the global problem of disease caused by pollution, improved programs of public health monitoring and environmental protecti...
Source: EHP Research - March 1, 2016 Category: Environmental Health Authors: Web Admin Tags: Brief Communication March 2016 Source Type: research